Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 726,346
  • Shares Outstanding, K 37,615
  • Annual Sales, $ 6,790 K
  • Annual Income, $ -44,360 K
  • 60-Month Beta N/A
  • Price/Sales 111.29
  • Price/Cash Flow N/A
  • Price/Book 2.64
Trade RNA with:

Options Overview

Details
  • Implied Volatility 100.92%
  • Historical Volatility 71.45%
  • IV Percentile 77%
  • IV Rank 73.37%
  • IV High 120.61% on 07/19/21
  • IV Low 46.69% on 07/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 40
  • Open Int (30-Day) 20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.76
  • Number of Estimates 2
  • High Estimate -0.69
  • Low Estimate -0.84
  • Prior Year -1.23
  • Growth Rate Est. (year over year) +38.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.85 +9.44%
on 07/27/21
26.88 -23.26%
on 07/12/21
-2.99 (-12.66%)
since 07/02/21
3-Month
18.85 +9.44%
on 07/27/21
29.59 -30.28%
on 06/28/21
-2.81 (-11.99%)
since 04/30/21
52-Week
18.85 +9.44%
on 07/27/21
37.46 -44.93%
on 09/15/20
-7.56 (-26.82%)
since 07/31/20

Most Recent Stories

More News
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today...

RNA : 20.63 (+6.84%)
Will Avidity Biosciences, Inc. (RNA) Report Negative Q2 Earnings? What You Should Know

Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RNA : 20.63 (+6.84%)
Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)

/PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced...

RNA : 20.63 (+6.84%)
Avidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event

, /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™),...

RNA : 20.63 (+6.84%)
Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

, /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™),...

RNA : 20.63 (+6.84%)
Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021

, /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™),...

RNA : 20.63 (+6.84%)
Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

, /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs), today...

RNA : 20.63 (+6.84%)
Avidity Biosciences to Participate in Upcoming Investor Conferences

, /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs), today...

RNA : 20.63 (+6.84%)
Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights

, /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today...

RNA : 20.63 (+6.84%)
Avidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference

, /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs), today...

RNA : 20.63 (+6.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the...

See More

Key Turning Points

3rd Resistance Point 23.01
2nd Resistance Point 21.96
1st Resistance Point 21.30
Last Price 20.63
1st Support Level 19.58
2nd Support Level 18.53
3rd Support Level 17.87

See More

52-Week High 37.46
Fibonacci 61.8% 30.35
Fibonacci 50% 28.15
Fibonacci 38.2% 25.96
Last Price 20.63
52-Week Low 18.85

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar